WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
  September 5 at 12:30pm ET
• Morgan Stanley 16th Annual Global Healthcare Conference
  September 13 at 3:30pm ET

A webcast of each presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005536/en/

INVESTOR RELATIONS CONTACT

ImmunoGen, Inc.

Sarah Kiely, 781-895-0600

[email protected]

or

MEDIA CONTACT

ImmunoGen, Inc.

Courtney O’Konek, 781-895-0600

[email protected]

or

FTI Consulting

Robert Stanislaro, 212-850-5657

[email protected]

Source: ImmunoGen, Inc.

Press Releases